Nucleoside Reverse Transcriptase Inhibitor (nrti) - Infectious Diseases

Relevant Publications

HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.

Issue Release: 2024

Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed.

Issue Release: 2024

Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study.

Issue Release: 2024

HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.

Issue Release: 2024

Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients.

Issue Release: 2024

Low HIV drug resistance prevalence among recently diagnosed HIV-positive men who have sex with men in a setting of high PrEP use.

Issue Release: 2024

Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial.

Issue Release: 2024

Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India.

Issue Release: 2024

Portable Nanopore sequencing solution for next-generation HIV drug resistance testing.

Issue Release: 2024

Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.

Issue Release: 2024

Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis.

Issue Release: 2023

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.

Issue Release: 2023

Human immunodeficiency virus 1 5\'-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations.

Issue Release: 2023

Genetic Diversity and Characteristics of Drug Resistance Among Treatment-Naive People Living with HIV in Xi\'an, China.

Issue Release: 2023

A National HIV Provider Survey of Antiretroviral Therapy Preferences for Management of Treatment-Naive and Experienced Individuals With Drug Resistance.

Issue Release: 2023

Comparative analysis of pre-existing HIV drug resistance mutations in proviral DNA via Next-Generation Sequencing and routine HIV RNA genotyping.

Issue Release: 2023

Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.

Issue Release: 2023

Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo: County, China.

Issue Release: 2023

Microglia and p38 MAPK Inhibitors Suppress Development of Mechanical Allodynia in Both Sexes in a Mouse Model of Antiretroviral-Induced Neuropathic Pain.

Issue Release: 2023

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).

Issue Release: 2023

Can Dexamethasone be used in all patients with infectious diseases?

How Do Surveillance Systems Work?

What are the global statistics?

What Role Do Respiratory Droplets Play in Super-Spreading Events?

What is the global impact of Plasmodium falciparum malaria?

Why is Drug Resistance a Concern?

How Do ID Specialists Stay Updated?

What are the Symptoms in Humans?

What Preventive Measures are Available?

Is there a Vaccine for West Nile Virus?

Nucleoside Reverse Transcriptase Inhibitor (nrti) - Infectious Diseases

Relevant Publications

Partnered Content Networks

Relevant Topics